Send us a link
US Policy Study Warns Swiss Pharma Industry Could Lose Billions
Does Europe Dare to Invest in the Arctic?
Prioritising long-term strategic investment in the Arctic requires courage, but it is a choice Europe cannot afford to postpone.
EU Access Charter Sends ‘Important Signal’ to Research and Technology Infrastructures
EU Access Charter Sends ‘Important Signal’ to Research and Technology Infrastructures
Voluntary framework aims to improve access for industry and start-ups and to speed up time to market.
Industry Rejects Move to Cash Contributions for EU Joint Undertakings
Industry Rejects Move to Cash Contributions for EU Joint Undertakings
The European Commission has received significant pushback to its suggestion that industry could be required to make cash rather than in kind contributions to Horizon Europe joint undertakings (JUs).
Absorbing Science Brief into Business Department ‘Makes Sense’
Absorbing Science Brief into Business Department ‘Makes Sense’
In the UK, Andy Burnham’s decision to absorb the science brief into an expanded business department could strengthen links between research and the government’s industrial strategy.
Mathematicians Warn of AI Threats to Profession as Industry Encroaches
Mathematicians Warn of AI Threats to Profession as Industry Encroaches
International Mathematical Union endorses warning about tech industry influence.
Academic Collaboration with Industry is No Longer Optional - It is Now Essential
Academic Collaboration with Industry is No Longer Optional - It is Now Essential
With funding cuts hampering academic science budgets, industrial science can play a pivotal role in supporting research.
Industrial Policy Can Benefit from Research, but Should Not Dictate Priorities, Ehler Says
Industrial Policy Can Benefit from Research, but Should Not Dictate Priorities, Ehler Says
Bridging the Gap Between Scientists, Policy Makers and Industry to Build the Quantum Ecosystem
Bridging the Gap Between Scientists, Policy Makers and Industry to Build the Quantum Ecosystem
How to Navigate the Challenges of Corporate-academia Research Partnerships
Many research projects draw on sources of funding from the corporate world. Fola Adeleke discusses the challenges inherent to this kind of research and outlines three key considerations for researchers engaging with corporate partners.
'Industry Scientists Are Often Misunderstood: Here’s Why I Chose This Path'
Leaving Academia for Industry? Here's How to Handle Salary Negotiations
Are Science and Technology Friends or Foes?
Does research based on a well-defined technological outcome hamper our ability to be creative? And does it limit opportunities to explore and develop fundamental areas of science that may ultimately lead to applications we hadn't even thought of yet?
How an Early Oil Industry Study Became Key in Climate Lawsuits
For decades, 1960s research for the American Petroleum Institute warning of the risks of burning fossil fuels had been forgotten. But two papers discovered in libraries are now playing a key role in lawsuits aimed at holding oil companies accountable for climate change.
Conflicts of Interest in Nutrition Research
This Medical News story examines the outcry over a recently published guideline that found insufficient evidence to recommend eating less red meat.
Twelve Million Phones, One Dataset, Zero Privacy
What we learned from the spy in your pocket.
In Unpublished Paper, Former White House Climate Adviser Calls Methane 'irrelevant' to Climate
Associations Between Industry Involvement and Study Characteristics at the Time of Trial Registration in Biomedical Research
Associations Between Industry Involvement and Study Characteristics at the Time of Trial Registration in Biomedical Research
Study investigates whether industry involvement in biomedical research affects trial design. A reduced use of active controls (such as alternate treatment or standard care) was found in trials with industry involvement, which can have the side effect of making results look more favourable than they actually are.
An HIV Treatment Cost Taxpayers Millions. The Government Patented It. But a Pharma Giant Is Making Billions.
An HIV Treatment Cost Taxpayers Millions. The Government Patented It. But a Pharma Giant Is Making Billions.
The extraordinary standoff between the CDC and a drug company over patent rights raises a big question for the Trump administration: How aggressively should the government attempt to enforce its patents against an industry partner?